The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Calgary
About this trial
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
Eligibility criteria
Qualifiers
Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND/OR
Pre-pregnancy BMI ≥30 kg/m²
Smoking in the current pregnancy or within 3 months prior to pregnancy
Previous clinical history of superficial vein thrombosis
Disqualifiers
More than 48 hours since delivery at the time of randomization
Received more than 1 dose of LMWH since delivery
Documented history of provoked or unprovoked VTE
Mechanical heart valve(s)
Trial design
Treatments tested in this trial
- Aspirin
- Low-molecular-weight heparin
Treatment groups
8,805 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Calgary
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Source ClinicalTrials.gov